SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 4, 2004
REPLIGEN CORPORATION
(Exact name of registration as specified in charter)
Delaware 0-14656 04-2729386
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 250-0111
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 5. Other Events.
Repligen Corporation and The Massachusetts Institute of Technology (MIT)
have filed an action for patent infringement against ImClone Systems, Inc. for
infringement of United States Patent No. 4,663,281 based on Imclone's
manufacture and sale of the recently-approved cancer drug Erbitux(R). The
technology, which was developed and patented by MIT, covers certain genetic
elements ("DNA enhancers") that increase protein production in a mammalian cell.
Repligen is the exclusive licensee of MIT for this patent. Repligen and MIT
believe that the cell line, which is used to manufacture Erbitux(R), was
developed by Damon Biotech, a predecessor of Repligen, in 1990 for the National
Cancer Institute and uses the technology which is the basis of the patent.
Repligen and MIT have filed an application for patent term extension for United
States Patent No. 4,663,281, which expires on May 5, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
REPLIGEN CORPORATION
Dated: May 5, 2004 By: /s/ Walter C. Herlihy
------------------------------------
Walter C. Herlihy
Chief Executive Officer and President